Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ridgeback Biotherapeutics

- PMLiVE

Merck’s Keytruda improves outcomes for metastatic cervical cancer patients

Keytruda improved overall survival and progression-free survival regardless of patients' PD-L1 status

- PMLiVE

GSK, Vir’s sotrovimab cuts hospitalisation and death risk by 79% in COVID-19 outpatients

Final efficacy analysis confirms previous positive findings from interim analysis

- PMLiVE

Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome

TNX-102 is already in phase 3 development for the treatment of fibromyalgia

- PMLiVE

Gilead reveals real-world data for COVID-19 drug Veklury

Veklury significantly lowered the risk of mortality compared with matched controls in real-world analysis, says Gilead

- PMLiVE

Court rules on AZ and EU’s COVID-19 vaccine dispute

The Court in Brussels has ordered AZ to deliver a total of 80.2 million doses to the EU by 27 September 2021

- PMLiVE

US announces $3bn funding boost for antiviral COVID-19 treatments

Funding will go towards the discovery, development and manufacturing of antiviral medicines

- PMLiVE

Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy

Vaccine candidate failed to meet prespecified measure of statistical success in clinical trial

- PMLiVE

Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses

Pfizer/BioNTech and AZ vaccines found to be 96% and 92% effective against variant, respectively

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

- PMLiVE

US trial data shows Novavax’s COVID-19 vaccine is 90% effective

The jab was also found to provide protection against variants of concern and variants of interest

- PMLiVE

AZ’s long-acting COVID-19 antibody fails to meet primary endpoint in prevention trial

AZD7442 is based on antibodies isolated from two patients who had recovered from COVID-19

- PMLiVE

G7 expected to donate one billion COVID-19 vaccine doses

At the same time, the FDA has extended the shelf-life of the single-dose J&J vaccine

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links